硫酸沙丁胺醇联合异丙托溴铵治疗COPD合并呼吸衰竭的疗效观察  

Therapeutic Effect of Salbutamol Sulfate Combined with Ipratropium Bromide on COPD Complicated with Respiratory Failure

在线阅读下载全文

作  者:丁志文 刘志伟[1] Zhiwen DING;Zhiwei LIU(Dongguan Huangjiang Hospital, Dongguan 523750, China)

机构地区:[1]东莞市黄江医院,广东东莞523750

出  处:《心电图杂志(电子版)》2017年第4期31-33,共3页Journal of Electrocardiogram(Electronic Edition)

摘  要:目的分析硫酸沙丁胺醇联合异丙托溴铵治疗慢性阻塞性肺疾病(COPD)合并呼吸衰竭的临床疗效。方法研究时段自2016年9月-2017年9月,选定本院收治的COPD合并呼吸衰竭患者80例,分组原则以入院顺序奇偶性,分对照组(40例,采纳硫酸沙丁胺醇治疗)、研究组(40例,在对照组基础上采纳异丙托溴铵联合治疗),比较临床疗效、肺功能。结果研究组临床总有效率(95.00%)显著较对照组(75.00%)高,研究组治疗后FEV1/FVC、FVC、FEV1水平显著较对照组高,具统计学差异(P<0.05)。结论硫酸沙丁胺醇与异丙托溴铵联合可有效改善COPD合并呼吸衰竭患者肺功能,减轻临床症状,效果显著,值得借鉴。Objective To analyze the clinical efficacy of salbutamol sulfate combined with ipratropium bromide in the treatment of chronic obstructive pulmonary disease (COPD) with respiratory failure. Methods From September 2016 to September 2017, 80 patients with COPD and respiratory failure admitted to our hospital were selected. The grouping principle was based on the parity of admission. The patients were divided into two groups: the control group (40 patients, treated with salbutamol sulfate) and the study group (40 cases, combined with ipratropium bromide on the basis of the control group). The clinical efficacy and lung function were compared. Results The total effective rate of the study group (95.00%) was significantly higher than that of the control group (75.00%). The levels of FEV1/FVC, FVC and FEV1 in the study group were significantly higher than those in the control group (P<0.05). Conclusion Salbutamol sulfate combined with ipratropium bromide can effectively improve lung function and reduce clinical symptoms in patients with COPD complicated with respiratory failure. The effect is significant and worth learning.

关 键 词:硫酸沙丁胺醇 异丙托溴铵 慢性阻塞性肺疾病 呼吸衰竭 疗效 

分 类 号:R563.9[医药卫生—呼吸系统] R563.8[医药卫生—内科学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象